These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 23765230)

  • 21. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants.
    Cymer F; Schlothauer T; Knaupp A; Beck H
    Bioanalysis; 2017 Sep; 9(17):1305-1317. PubMed ID: 28901177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.
    Gao X; Ji JA; Veeravalli K; Wang YJ; Zhang T; Mcgreevy W; Zheng K; Kelley RF; Laird MW; Liu J; Cromwell M
    J Pharm Sci; 2015 Feb; 104(2):368-77. PubMed ID: 25175600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins.
    Chung S; Lin YL; Nguyen V; Kamen L; Zheng K; Vora B; Song A
    J Immunol Methods; 2018 Nov; 462():101-105. PubMed ID: 30030147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
    Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.
    Raghavan M; Bonagura VR; Morrison SL; Bjorkman PJ
    Biochemistry; 1995 Nov; 34(45):14649-57. PubMed ID: 7578107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
    Reusch J; Andersen JT; Rant U; Schlothauer T
    MAbs; 2024; 16(1):2361585. PubMed ID: 38849969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural insights into neonatal Fc receptor-based recycling mechanisms.
    Oganesyan V; Damschroder MM; Cook KE; Li Q; Gao C; Wu H; Dall'Acqua WF
    J Biol Chem; 2014 Mar; 289(11):7812-24. PubMed ID: 24469444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
    Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
    Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G.
    Zhou J; Johnson JE; Ghetie V; Ober RJ; Ward ES
    J Mol Biol; 2003 Sep; 332(4):901-13. PubMed ID: 12972260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein.
    Suzuki T; Hashii N; Tada M; Ishii-Watabe A
    MAbs; 2021; 13(1):1923366. PubMed ID: 34030575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Robust expression of the human neonatal Fc receptor in a truncated soluble form and as a full-length membrane-bound protein in fusion with eGFP.
    Seijsing J; Lindborg M; Löfblom J; Uhlén M; Gräslund T
    PLoS One; 2013; 8(11):e81350. PubMed ID: 24260574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
    Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
    MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.
    Feng Y; Gong R; Dimitrov DS
    Protein Expr Purif; 2011 Sep; 79(1):66-71. PubMed ID: 21453773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
    Jensen PF; Schoch A; Larraillet V; Hilger M; Schlothauer T; Emrich T; Rand KD
    Mol Cell Proteomics; 2017 Mar; 16(3):451-456. PubMed ID: 28062799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detailed Characterization of Monoclonal Antibody Receptor Interaction Using Affinity Liquid Chromatography Hyphenated to Native Mass Spectrometry.
    Gahoual R; Heidenreich AK; Somsen GW; Bulau P; Reusch D; Wuhrer M; Haberger M
    Anal Chem; 2017 May; 89(10):5404-5412. PubMed ID: 28398745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.